



PURGED

Food and Drug Administration
Minneapolis District
240 Hennepin Avenue
Minneapolis MN 55401-1999
Telephone: 612-334-4100

July 10, 2000

WARNING LETTER

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Refer to MIN 00 - 43

John F. Schuler
Chief Executive Officer
Columbia Hospital
2015 East Newport Avenue
Milwaukee, Wisconsin 53207

Dear Mr. Schuler:

We are writing to you because on June 27, 2000, a representative of the State of Wisconsin, acting on behalf of the Food and Drug Administration (FDA), inspected your facility, Bayview Family Health Center, 3056 S. Kinnickinnic Avenue, Milwaukee, WI. This inspection (ID # 2013430006) revealed a serious regulatory problem involving the mammography at your facility.

Under a United States Federal law, the Mammography Quality Standards Act of 1992, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following Level 1, Level 2, and repeat Level 3 findings at your facility:

Level 1 Non-Compliance:

1. The system to communicate results is inadequate for the Bayview Family Health Center site because there is no system in place to provide timely lay summaries to all patients, regardless of their assessment category.


Level 2 Non-Compliance:

2. One of 9 random reports reviewed did not contain an assessment category for the Bayview Family Health Center site.

Page Two

John F. Schuler

July 10, 2000

3. Interpreting physician  did not meet the continuing experience requirement of having read or interpreted 960 patient examinations in a 24-month period.

The specific problems noted above appeared on your MQSA Facility Inspection Report which was issued to your facility following the close of the inspection.

Individuals failing to meet either the "Initial" and/or "Continuing" MQSA requirements must immediately cease performing mammography independently. For physicians, the "Continuing" requirements include either the lack of appropriate CME/24 months or Number of Interpretations/36 months. Requirements for re-qualification are listed in the Final Regulation that became effective on April 28, 1999.

Because these conditions may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, they represent a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

It is necessary for you to act on this matter immediately. Please explain to this office in writing within 15 working days from the date you received this letter:

- the specific steps you have taken to correct all of the violations noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations;
- equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and
- sample records that demonstrate proper record keeping procedures if the findings relate to quality control or other records.

Please submit your response to Thomas W. Garvin, Radiological Health Specialist, FDA, 2675 N. Mayfair Road, Suite 200, Milwaukee, WI 53226-1305.

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug

Page Three


John F. Schuler

July 10, 2000


Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at <http://www.fda.gov/cdrh/mammography/index.html>.

If you have specific questions about mammography facility requirements or about the content of this letter please feel free to phone Mr. Garvin at (414) 771-7167 ext. 12.

Sincerely,


James A. Rahto
Director
Minneapolis District

TGP/ccl

xc: 
Lead Interpreting Physician
c/o Bayview Family Health Center
3036 S. Kinnickinnic Avenue
Milwaukee, WI 53207

Paul Schmidt
Chief, Radiation Protection Unit
State of Wisconsin
P.O. Box 2659
Madison, WI 53701-2659

Priscilla F. Butler
Director, Breast Imaging Accreditation Programs
Standards/Accreditation Department
American College of Radiology
1891 Preston White Drive
Reston, VA 20191